Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Disease Progression × Filgrastim × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma 183 Leukemia 143 Leukemia, Myeloid, Acute 122 Precursor Cell Lymphoblastic Leukemia-Lymphoma 119 Lymphoma, Non-Hodgkin 103 Multiple Myeloma 100 Lymphoma, Large B-Cell, Diffuse 99 Lymphoma, Follicular 84 Burkitt Lymphoma 84 Hodgkin Disease 83 Lymphoma, Mantle-Cell 78 Myelodysplastic Syndromes 76 Breast Neoplasms 76 Leukemia, Lymphocytic, Chronic, B-Cell 75 Lymphoma, Large-Cell, Immunoblastic 67 Lymphoma, B-Cell, Marginal Zone 55 Sarcoma 48 Neoplasms, Plasma Cell 45 Central Nervous System Neoplasms 39 Recurrence 38 Neuroblastoma 38 Leukemia, Myeloid, Chronic-Phase 38 Leukemia, Myeloid, Accelerated Phase 36 Dendritic Cell Sarcoma, Interdigitating 36 Myeloproliferative Disorders 34 Congenital Abnormalities 33 Blast Crisis 33 Ovarian Neoplasms 32 Leukemia, Myelomonocytic, Chronic 29 Neutropenia 27

Interventions

Lenalidomide 4 Dexamethasone 4 Cyclophosphamide 4 Bortezomib 4 Cisplatin 3 Carboplatin 3 vandetanib 2 tumor necrosis factor-alpha, CNGRC fusion protein, human 2 pomalidomide 2 pembrolizumab 2 liposomal doxorubicin 2 fludarabine 2 durvalumab 2 capivasertib 2 Radiosurgery 2 Paclitaxel 2 Nivolumab 2 Gemcitabine 2 Doxorubicin 2 Bevacizumab 2 Anthropogenic Effects 2 venetoclax 1 umbralisib 1 ublituximab 1 tremelimumab 1 tivozanib 1 ricolinostat 1 pazopanib 1 niraparib 1 nilotinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02043847 2024-11-13

BMT-03

University of Illinois at Chicago

Phase 1 Completed

12 enrolled 12 charts

Multiple Myeloma, Recurrence, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon ⚡